Recursion Pharmaceuticals
Corporate ownership and the company’s role in compute infrastructure.
TypeOtherHQUS
Loading company data…
Corporate ownership and the company’s role in compute infrastructure.
Loading company data…
The main chain follows the strongest parent claim by confidence, source authority and date. Other named parents appear alongside it.
Starting organisation.
The displayed ownership chain ends at Recursion Pharmaceuticals (CIK 1601830)
Sovereign investors committed capital to funds whose portfolios include this company. A commitment covers the fund’s portfolio, so its amount cannot be assigned to this company. Fund names and amounts are held under subscription and not redistributed. Dates refer to the original commitments; current holdings require separate verification. Investment methodology.
| Sovereign limited partner | Commitments | Dated | Amount disclosed | 12+ years old | Source status |
|---|---|---|---|---|---|
| Mubadala Investment Company | 7 | 5 of 7 · 2018–2021 | 2 of 7 | — | Current |
| GIC Private | 3 | 3 of 3 · 2001 | none | 3 | Current |
| Saudi Arabia's Public Investment Fund | 3 | 3 of 3 · 2018–2019 | 2 of 3 | — | Current |
| Qatar Investment Authority | 2 | 2 of 2 · 2018 | 2 of 2 | — | Current |
Amount disclosed counts commitments with a dollar figure in the source; these amounts are withheld under licence. 12+ years old counts dated fund commitments that meet this age threshold. Source: Documented ownership record · vintage 2026-04-24 · tier 2
Sites attributed to this company as owner, operator or AI-hardware owner.
Scrutica holds licensed supply-chain records for this company. The sovereign fund commitments above come from a licensed fund/LP database. Geographic revenue, business segments and capital allocation are unavailable from the corporate-financial extract. The corporate-financial extract holds no row for Recursion Pharmaceuticals. The public industry classification (SIC, NAICS) is also unrecorded. Sources and publication limits.